Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin

Infection and Immunity

Volumn 81, Issue 12, 2013, Pages 4350-4362

  Carapau, Daniel ^a,c   Mitchell, Robert ^a   Nacer, Adéla ^a,d   Shaw, Alan ^b,e   Othoro, Caroline ^a   Frevert, Ute ^a   Nardin, Elizabeth ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VaxInnate Corporation   (United States)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d INSTITUT PASTEUR   (France)

^e Vedantra Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; CHIMERIC PROTEIN; CIRCUMSPOROZOITE PROTEIN; FLAGELLIN MODIFIED CHIMERIC CIRCUMSPOROZOITE PROTEIN VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 5; MALARIA VACCINE; NEUTRALIZING ANTIBODY; PROTOZOON ANTIBODY; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; EPITOPE; FLAGELLIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; SUBUNIT VACCINE; TLR5 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE; T LYMPHOCYTE; TH1 TH2 BALANCE; VACCINATION; VACCINE IMMUNOGENICITY; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DENDRITIC CELL; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MALARIA, FALCIPARUM; PARASITOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, PROTOZOAN; CELLS, CULTURED; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FLAGELLIN; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-5; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SPOROZOITES; TOLL-LIKE RECEPTOR 5; VACCINES, SUBUNIT;

EID: 84891692328     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00263-13     Document Type: Article

References (69)

1. Nussenzweig RS, Vanderberg J, Most H, Orton C. 1967. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 216:160-162.
2. Clyde DF. 1975. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am. J. Trop. Med. Hyg. 24:397- 401.
3. Clyde DF. 1990. Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull. World Health Organ. 68(Suppl):9-12.
4. Rieckmann KH. 1990. Human immunization with attenuated sporozoites. Bull. World Health Organ. 68(Suppl):13-16.
5. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. 1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207:71-73.
6. Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, Tapchaisri P, Chomcharn Y. 1982. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156:20-30.
7. Kumar KA, Sano G, Boscardin S, Nussenzweig RS, Nussenzweig MC, Zavala F, Nussenzweig V. 2006. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444:937-940.
8. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita MC, Kabore W, Ouedraogo S, Sandrine Y, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Odero C, Oneko M, Otieno K, Awino N, Omoto J, Williamson J, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Nekoye O, Gondi S, Otieno A, Ogutu B, Wasuna R, Owira V, Jones D, Onyango AA, Njuguna P, Chilengi R, Akoo P, Kerubo C, Gitaka J, Maingi C, Lang T, Olotu A, Tsofa B, Bejon P, Peshu N, Marsh K, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Ayamba S, Kayan K, Owusu-Ofori R, Dosoo D, Asante I, Adjei G, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Kilavo H, Mahende C, Liheluka E, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Agyekum A, Owusu L, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Msika A, Jumbe A, Chome N, Nyakuipa D, Chintedza J, Ballou WR, Bruls M, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori- Anyinam O, Vekemans J, Carter T, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. 2011. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365:1863-1875.
9. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods JB, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander TG, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou WR, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284-2295.
10. Stoute JA, Heppner DG, Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR. 2006. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. Am. J. Trop. Med. Hyg. 75:166-170.
11. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, La- Chance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M, Hauser P, Voet P, Sadoff JC, Ballou WR. 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171:1576-1585.
12. Owusu-Agyei S, Ansong D, Asante K, Kwarteng Owusu S, Owusu R, Wireko Brobby NA, Dosoo D, Osei Akoto A, Osei-Kwakye K, Adjei EA, Boahen KO, Sylverken J, Adjei G, Sambian D, Apanga S, Kayan K, Vekemans J, Ofori-Anyinam O, Leach A, Lievens M, Demoitie MA, Dubois MC, Cohen J, Ballou WR, Savarese B, Chandramohan D, Gyapong JO, Milligan P, Antwi S, Agbenyega T, Greenwood B, Evans J. 2009. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One 4:e7302. doi:10.1371/journal.pone.0007302.
13. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG, Jr. 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/ AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200:337-346.
14. Pulendran B, Ahmed R. 2006. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124:849- 863.
15. Coffman RL, Sher A, Seder RA. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33:492-503.
16. Pulendran B, Ahmed R. 2011. Immunological mechanisms of vaccination. Nat. Immunol. 12:509-517.
17. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099-1103.
18. McEwen J, Levi R, Horwitz RJ, Arnon R. 1992. Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. Vaccine 10:405-411.
19. Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ. 2007. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25:763-775.
20. McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ. 2007. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195:1607- 1617.
21. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ. 2008. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201-214.
22. Bargieri DY, Rosa DS, Braga CJ, Carvalho BO, Costa FT, Espindola NM, Vaz AJ, Soares IS, Ferreira LC, Rodrigues MM. 2008. New malaria vaccine candidates based on the Plasmodium vivax merozoite surface protein- 1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26:6132-6142.
23. Mizel SB, Bates JT. 2010. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol. 185:5677-5682.
24. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, Shaw AR, Taylor DN. 2010. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 5:e14442. doi:10.1371/journal.pone .0014442.
25. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I, Shaw A. 2010. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28:8268-8274.
26. Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A. 2011. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29:4897-4902.
27. Nardin EH, Herrington DA, Davis J, Levine M, Stuber D, Takacs B, Caspers P, Barr P, Altszuler R, Clavijo P, Nussenzweig RS. 1989. Conserved repetitive epitope recognized by CD4 clones from a malariaimmunized volunteer. Science 246:1603-1606.
28. Moreno A, Clavijo P, Edelman R, Davis J, Sztein M, Sinigaglia F, Nardin E. 1993. CD4 T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J. Immunol. 151:489-499.
29. Calvo-Calle JM, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro ZR, Nardin EH. 1997. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J. Immunol. 159:1362-1373.
30. Eaves-Pyles TD, Wong HR, Odoms K, Pyles RB. 2001. Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. J. Immunol. 167:7009- 7016.
31. Stockinger B, Zal T, Zal A, Gray D. 1996. B cells solicit their own help from T cells. J. Exp. Med. 183:891-899.
32. Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinman RM, Mellman I. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388:787-792.
33. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L, Zimmermann VS, Davoust J, Ricciardi-Castagnoli P. 1997. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J. Exp. Med. 185:317-328.
34. O'Neill DW, Bhardwaj N. 2005. Differentiation of peripheral blood monocytes into dendritic cells. Curr. Protoc. Immunol. Chapter 22:Unit 22F.4. doi:10.1002/0471142735.im22f04s67.
35. Kiyono H, Fukuyama S. 2004. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4:699-710.
36. Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, Nardin E. 2002. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J. Immunol. 169:6681-6685.
37. Othoro C, Johnston D, Lee R, Soverow J, Bystryn JC, Nardin E. 2009. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect. Immun. 77:739-748.
38. Bruna-Romero O, Hafalla JC, Gonzalez-Aseguinolaza G, Sano G, Tsuji M, Zavala F. 2001. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int. J. Parasitol. 31:1499-1502.
39. Nussenzweig RS. 1967. Increased nonspecific resistance to malaria produced by administration of killed Corynebacterium parvum. Exp. Parasitol. 21:224-231.
40. Vanderberg JP, Nussenzweig RS, Most H. 1968. Further studies on the Plasmodium berghei-Anopheles stephensi-rodent system of mammalian malaria. J. Parasitol. 54:1009-1016.
41. Schmidt LH, Fradkin R, Genther CS, Rossan RN, Squires W. 1982. The characteristics of untreated sporozoite-induced and trophozoite-induced infections. Am. J. Trop. Med. Hyg. 31:612-645.
42. Vanderberg J, Nussenzweig R, Most H. 1969. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. Mil. Med. 134:1183- 1190.
43. Kumar KA, Oliveira GA, Edelman R, Nardin E, Nussenzweig V. 2004. Quantitative Plasmodium sporozoite neutralization assay (TSNA). J. Immunol. Methods 292:157-164.
44. Flanagan KL, Lee EA, Gravenor MB, Reece WH, Urban BC, Doherty T, Bojang KA, Pinder M, Hill AV, Plebanski M. 2001. Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J. Immunol. 167:4729-4737.
45. Bates JT, Uematsu S, Akira S, Mizel SB. 2009. Direct stimulation of Tlr5 / CD11c cells is necessary for the adjuvant activity of flagellin. J. Immunol. 182:7539-7547.
46. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. 2003. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J. Immunol. 170:5165- 5175.
47. Cochrane AH, Aikawa M, Jeng M, Nussenzweig RS. 1976. Antibodyinduced ultrastructural changes of malarial sporozoites. J. Immunol. 116: 859-867.
48. Vijay-Kumar M, Carvalho FA, Aitken JD, Fifadara NH, Gewirtz AT. 2010. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur. J. Immunol. 40:3528-3534.
49. Blander JM, Medzhitov R. 2004. Regulation of phagosome maturation by signals from Toll-like receptors. Science 304:1014-1018.
50. Blander JM, Medzhitov R. 2006. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440:808-812.
51. Ciacci-Woolwine F, McDermott PF, Mizel SB. 1999. Induction of cytokine synthesis by flagella from gram-negative bacteria may be dependent on the activation or differentiation state of human monocytes. Infect. Immun. 67:5176-5185.
52. Honko AN, Mizel SB. 2005. Effects of flagellin on innate and adaptive immunity. Immunol. Res. 33:83-101.
53. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, Pulendran B. 2003. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171:4984-4989.
54. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. 1980. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151: 1504-1513.
55. Ak M, Bower JH, Hoffman SL, Sedegah M, Lees A, Carter M, Beaudoin RL, Charoenvit Y. 1993. Monoclonal antibodies of three different immunoglobulinGisotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites. Infect. Immun. 61:2493-2497.
56. Stewart MJ, Nawrot RJ, Schulman S, Vanderberg JP. 1986. Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoiteimmobilizing antibodies. Infect. Immun. 51:859-864.
57. Vanderberg JP, Frevert U. 2004. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int. J. Parasitol. 34:991-996.
58. Kuper CF, Koornstra PJ, Hameleers DM, Biewenga J, Spit BJ, Duijvestijn AM, van Breda Vriesman PJ, Sminia T. 1992. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13:219-224.
59. van der Ven I, Sminia T. 1993. The development and structure of mouse nasal-associated lymphoid tissue: an immuno- and enzymehistochemical study. Reg. Immunol. 5:69-75.
60. Nacer A, Carapau D, Mitchell R, Meltzer A, Shaw A, Frevert U, Nardin EH. 3 July 2013. Imaging murine NALT following intranasal immunization with flagellin-modified circumsporozoite protein malaria vaccines. Mucosal Immunol. doi:10.1038/mi.2013.48.
61. Chieppa M, Rescigno M, Huang AY, Germain RN. 2006. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J. Exp. Med. 203:2841-2852.
62. Neutra MR, Mantis NJ, Kraehenbuhl JP. 2001. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat. Immunol. 2:1004-1009.
63. Davis SS. 2001. Nasal vaccines. Adv. Drug Deliv. Rev. 51:21-42.
64. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Ziegler T, Heikkinen T. 2011. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect. Dis. 11:23-29.
65. Przysiecki C, Lucas B, Mitchell R, Carapau D, Wen Z, Xu H, Wang XM, Nahas D, Wu C, Hepler R, Ottinger E, Ter Meulen J, Kaslow D, Shiver J, Nardin E. 2012. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex. Front. Cell. Infect. Microbiol. 2:146. doi:10.3389/fcimb.2012.00146.
66. Kobayashi T, Fukushima K, Sannan T, Saito N, Takiguchi Y, Sato Y, Hasegawa H, Ishikawa K. 2013. Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines. Viral Immunol. 26:133-142.
67. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD, Paranjape R, Kulkarni S, Rao DN. 2005. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 23:5599-5617.
68. Kataoka K, Fujihashi K, Oma K, Fukuyama Y, Hollingshead SK, Sekine S, Kawabata S, Ito HO, Briles DE, Oishi K. 2011. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect. Immun. 79:2819-2828.
69. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M. 2011. A research agenda to underpin malaria eradication. PLoS Med. 8:e1000406. doi:10.1371/journal.pmed.1000406.